Randomized Trialvery high evidence
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
The New England journal of medicine·January 30, 2025·PMID 39555826
Why it mattersThis is the first trial to show a dual GIP/GLP-1 receptor agonist improves clinical outcomes in HFpEF with obesity, a population with limited effective therapies. It provides a new evidence-based treatment option targeting both metabolic and cardiovascular pathways.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled